RE:RE:RE:RE:Theralase Is still Flying Under the RadarEoganacht ... Indeed, Dr. Kamat's initial mandate was not to promote our drug. But to advise Theralase in the design of the Ph. 2.
Contrary to the other drugs mentioned (N-803 with BCG, ...), these drugs have completed their trials, which is not the case of TLT yet. But for sure, if we obtain Breakthrough designation, this will be much easier for Dr. Kamat to put things into perspectives, talk about it in a non-partisan way and more in a scientifical way.